Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Finasteride,Tadalafil
Therapeutic Area : Urology
Study Phase : Approved FDF
Recipient : Onconetix
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The combined company will focus on the R&D and commercialization of proprietary science and technologies for therapeutics, including Entadfi, a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a PDE5...
Product Name : Entadfi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Finasteride,Tadalafil
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Recipient : Onconetix
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : BWV-401
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Texas Health Science Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, BWV will fund the NHP study to further evaluate the efficacy of BWV-401, a live attenuated, orally delivered Chlamydia vaccine, and provide additional support for development towards human clinical trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 04, 2023
Lead Product(s) : BWV-401
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Texas Health Science Center
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Virus-like Particle Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary preclinical data supporting the use of its norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform to develop a novel monkeypox vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : Virus-like Particle Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Finasteride,Tadalafil
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : IQVIA
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Blue Water Biotech and IQVIA will market Blue Water’s commercial portfolio including, Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for benign prostatic hyperplasia and Zontivity (vorapaxar).
Product Name : Entadfi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 21, 2023
Lead Product(s) : Finasteride,Tadalafil
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : IQVIA
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Levoamlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : WraSer Pharmaceuticals
Deal Size : $8.5 million
Deal Type : Acquisition
Details : Blue Water expands its commercial portfolio by purchasing six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. The assets also include Conjupri (levamlodipine), a calcium channel blocker for the...
Product Name : Conjupri
Product Type : Other Small Molecule
Upfront Cash : $8.5 million
June 14, 2023
Lead Product(s) : Levoamlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : WraSer Pharmaceuticals
Deal Size : $8.5 million
Deal Type : Acquisition
Lead Product(s) : Finasteride,Tadalafil
Therapeutic Area : Urology
Study Phase : Approved FDF
Recipient : Veru
Deal Size : $100.0 million
Deal Type : Agreement
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Details : The acquisition transforms the Company into a broader pharmaceutical company spanning multiple sectors by including ENTADFI (finasteride), an oral, once daily treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a PDE5 i...
Product Name : Entadfi
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
April 20, 2023
Lead Product(s) : Finasteride,Tadalafil
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Recipient : Veru
Deal Size : $100.0 million
Deal Type : Agreement
Lead Product(s) : Monkeypox Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : AbVacc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Blue Water Vaccines and AbVacc will collaborate for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease. Both candidate vaccines will utilize BWV’s norovirus shell and protrusion VLP platform.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 02, 2023
Lead Product(s) : Monkeypox Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : AbVacc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Chlamydia Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Texas Health San Antonio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Blue Water Vaccines Announces Agreement for Chlamydia Development
Details : Chlamydia vaccines have historically been challenging to produce, but the novel approach has demonstrated strong results in mouse models, which will translate into a human vaccine candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
November 21, 2022
Lead Product(s) : Chlamydia Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Texas Health San Antonio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BWV-201
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New data, based on experiments at St. Jude Children’s Research Hospital, suggests that BWV-201 may also provide protection against pneumococcal pneumonia by limiting the ability of Streptococcus pneumoniae to infect the lungs.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : BWV-201
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BWV-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Private Placement
Details : The Company intends to use the net proceeds from the private placement for the research and development of its pipeline as well as for working capital and other general corporate purposes.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
November 08, 2022
Lead Product(s) : BWV-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Private Placement